• Vipin A. M. Kerala Agricultural University
  • Bincy Baby Kerala Agricultural University
  • Bincy Baby Kerala Agricultural University
  • Mala S. Kumar Kerala Agricultural University
  • Mala S. Kumar Kerala Agricultural University
  • Ravisankar V. Kerala Agricultural University
  • P.a. Nazeem Kerala Agricultural University


Type 2 diabetes, Dipeptidyl peptidase 4, Glucagon like peptide-1, Discovery Studio 35


Objective: The aim of our study was to validate the accuracy of computational tools in drug discovery and molecular interaction studies by studying the inhibitory activity of various commercial drugs on DPP-4.

Methods: In order to validate the accuracy of computational tools, 50 commercially available drugs were docked with DPP-4, a major target for type 2 diabetes treatment. Studies were performed using Discovery studio 3.5.

Results: The analysis showed that out of the fifty selected drugs, 33 drugs passed the Lipinski's rule and commercially prescribed drugs namely Sulfonylurea, Pregabalin and Metaformin were found to have maximum interaction with the target.

Conclusion: These major drugs which yielded the best results were found to be used in the treatment of diabetes which reconfirms the efficacy of these drugs, druggability of the target as well as the accuracy of the tool used.


Download data is not yet available.


Lin Y, Sun Z. Current views on type 2 diabetes. J Endocrinol 2010;204(1):1-11.

American Diabetes Association. Diagnosis and classiï¬cation of diabetes mellitus. Diabetes Care 2004;27 Suppl 1:S5-S10.

Tansi FL, Blanchard V, Berger M, Tauber R, Reutter W, Fan H. Interaction of human dipeptidyl peptidase IV and human immunodeficiency virus type-1 transcription transactivator in Sf9 cells. Virol J 2010;7:267.

Shankaraiah P, Reddy YN. Bioflavonoids Inhibits Dipeptidyl Peptidase–IV Expressions in Diabetic Rats. Int J Pharm Res Scholars 2013;2(4):390-7.

Almasri IM, Taha MO, Mohammad MK. New leads for DPP IV inhibition: a structure-based pharmacophore mapping and virtual screening study. Arch Pharm Res 2013;36(11):1326-37.

Vijayakumari M, Minil M, Sathiyaraj U, Kavimani S. Linagliptin-a novel dpp-iv inhibitor. Int J Pharm Bio Sci 2011;2:438-42.

Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011;13(1):7-18.

Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 2006;3(3):159-65.

Bolton E, Wang Y, Thiessen PA, Bryant SH. Pub chem: integrated platform of small molecules and biological activities. Annu Rep Comput Chem 2008;4:217-40.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46(1-3):3-26.



How to Cite

M., V. A., B. Baby, B. Baby, M. S. Kumar, M. S. Kumar, R. V., and P. Nazeem. “COMPARATIVE DOCKING STUDIES ON THE EFFECT OF COMMERCIAL DRUGS ON DIPEPTIDYL PEPTIDASE-4 (DPP-4)”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 7, no. 1, Jan. 2015, pp. 508-10,



Short Communication(s)